Ken Fisher's LGND Position Overview
Ken Fisher (via Fisher Asset Management, LLC) currently holds 130,858 shares of Ligand Pharmaceuticals Incorporated (LGND) worth $24.74 M, representing 0.01% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 47 quarters.
Based on 13F filings since 2013, Ken Fisher has maintained a long-term strategic position in LGND, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2014, adding 46,650 shares. Largest reduction occurred in Q1 2021, reducing 61,429 shares.
Analysis based on 13F filings available since 2013 Q2
Ken Fisher's Ligand Pharmaceuticals Incorporated (LGND) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ligand Pharmaceuticals Incorporated (LGND) Trades by Ken Fisher
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +21,932 | Add 20.13% | 130,858 | $189.07 |
| Q3 2025 | +2,860 | Add 2.70% | 108,926 | $177.14 |
| Q2 2025 | -1,440 | Reduce 1.34% | 106,066 | $113.68 |
| Q1 2025 | +6,868 | Add 6.82% | 107,506 | $105.14 |
| Q4 2024 | +41,064 | Add 68.93% | 100,638 | $107.15 |
| Q3 2024 | +6,555 | Add 12.36% | 59,574 | $100.09 |
| Q2 2024 | -358 | Reduce 0.67% | 53,019 | $84.26 |
| Q1 2024 | +4,080 | Add 8.28% | 53,377 | $73.10 |
| Q4 2023 | +16,035 | Add 48.21% | 49,297 | $71.42 |
| Q3 2023 | -2,563 | Reduce 7.15% | 33,262 | $59.92 |
| Q2 2023 | -4,075 | Reduce 10.21% | 35,825 | $72.10 |
| Q1 2023 | +242 | Add 0.61% | 39,900 | $73.56 |
| Q4 2022 | +11,368 | Add 40.18% | 39,658 | $66.80 |
| Q3 2022 | +20,859 | Add 280.70% | 28,290 | $86.11 |
| Q2 2022 | -40 | Reduce 0.54% | 7,431 | $89.22 |
| Q1 2022 | +40 | Add 0.54% | 7,471 | $112.43 |
| Q4 2021 | -3 | Reduce 0.04% | 7,431 | $154.49 |
| Q3 2021 | +1,191 | Add 19.08% | 7,434 | $139.36 |
| Q2 2021 | +225 | Add 3.74% | 6,243 | $131.19 |
| Q1 2021 | -61,429 | Reduce 91.08% | 6,018 | $152.38 |
| Q4 2020 | -2,548 | Reduce 3.64% | 67,447 | $99.46 |
| Q3 2020 | -4,443 | Reduce 5.97% | 69,995 | $95.32 |
| Q2 2020 | -3,908 | Reduce 4.99% | 74,438 | $111.85 |
| Q1 2020 | -8,581 | Reduce 9.87% | 78,346 | $72.72 |
| Q4 2019 | -11,271 | Reduce 11.48% | 86,927 | $104.29 |
| Q3 2019 | +12,750 | Add 14.92% | 98,198 | $99.54 |
| Q2 2019 | +13,692 | Add 19.08% | 85,448 | $114.15 |
| Q1 2019 | +5,651 | Add 8.55% | 71,756 | $125.70 |
| Q4 2018 | +23,486 | Add 55.11% | 66,105 | $135.69 |
| Q3 2018 | -2,115 | Reduce 4.73% | 42,619 | $274.48 |
| Q2 2018 | -2,184 | Reduce 4.65% | 44,734 | $207.18 |
| Q1 2018 | -8,143 | Reduce 14.79% | 46,918 | $165.16 |
| Q4 2017 | -1,294 | Reduce 2.30% | 55,061 | $136.94 |
| Q3 2017 | -3,945 | Reduce 6.54% | 56,355 | $136.15 |
| Q2 2017 | -90 | Reduce 0.15% | 60,300 | $121.39 |
| Q1 2017 | -5,100 | Reduce 7.79% | 60,390 | $105.85 |
| Q4 2016 | -6,900 | Reduce 9.53% | 65,490 | $101.60 |
| Q2 2016 | +1,807 | Add 2.56% | 72,390 | $126.76 |
| Q4 2015 | -100 | Reduce 0.14% | 70,583 | $108.43 |
| Q3 2015 | -9,925 | Reduce 12.31% | 70,683 | $85.65 |
| Q2 2015 | -1,300 | Reduce 1.59% | 80,608 | $100.90 |
| Q4 2014 | +46,650 | Add 132.31% | 81,908 | $53.21 |
| Q3 2014 | -1,650 | Reduce 4.47% | 35,258 | $47.00 |
| Q2 2014 | +36,908 | New Buy | 36,908 | $62.29 |
Ken Fisher's Ligand Pharmaceuticals Incorporated Investment FAQs
Ken Fisher first purchased Ligand Pharmaceuticals Incorporated (LGND) in Q2 2014, acquiring 36,908 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher has held Ligand Pharmaceuticals Incorporated (LGND) for 47 quarters since Q2 2014.
Ken Fisher's largest addition to Ligand Pharmaceuticals Incorporated (LGND) was in Q4 2014, adding 81,908 shares worth $4.36 M.
According to the latest 13F filing for Q4 2025, Ken Fisher's firm, Fisher Asset Management, LLC, owns 130,858 shares of Ligand Pharmaceuticals Incorporated (LGND), valued at approximately $24.74 M.
As of the Q4 2025 filing, Ligand Pharmaceuticals Incorporated (LGND) represents approximately 0.01% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.
Ken Fisher's peak holding in Ligand Pharmaceuticals Incorporated (LGND) was 130,858 shares, as reported at the end of Q4 2025.